A Phase 2 interventional study of TAK-951 and Ondansetron in Postoperative Nausea and Vomiting (PONV), sponsored by Takeda. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Takeda · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing ondansetron in Postoperative Nausea and Vomiting — 2 open to participants now, 3 under way, none of them phase 3. Ondansetron · Postoperative Nausea and Vomiting.
Among the 42 studies testing ondansetron in Postoperative Nausea and Vomiting, this one is the 32nd largest by enrollment, is one of 4 that started in 2020, is one of 3 in phase 2, and was the 26th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 42 studies testing ondansetron in Postoperative Nausea and Vomiting are open now, in 3 countries. Recruiting first, the newest first:
Faisalabad Medical University · Sites in Pakistan
Ages 18+
Telethon Kids Institute · Sites in Australia, Brazil
Ages 2–15
By country, each count listing its studies:
Ondansetron: first FDA approval 1991 (ZOFRAN). What it is approved for, and how studies give it, is on its page →
Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 4 · Phase 4 24
First in 2004; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is below the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 121 across the 42 interventional studies. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 1 study filed under Postoperative Nausea and Vomiting — fewer than ten, so there is no comparison to draw.
1 of the studies testing ondansetron in Postoperative Nausea and Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07638527Faisalabad Medical UniversityTime to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing ondansetron in Postoperative Nausea and Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Some adults are at a higher risk of feeling sick (nausea) or being sick (vomiting) after they have surgery. In this study, these adults will have planned surgery. The main aim of this study is to learn if TAK-951 stops these adults from getting nausea or vomiting after surgery. This will be compared with another medicine called ondansetron. Another aim is to check for side effects from the study medicines.
Before surgery, the study doctor will check who can take part in this study. Those who can take part will be picked for either Treatment Group A or Treatment Group B by chance.
Participants will not know which study medicines they received, or in which order, nor will their study doctors or surgeons. This is to help make sure the results are more reliable.
Participants will stay in the hospital for 24 hours after their surgery so that the study doctors can check for nausea and vomiting. The study doctors will also check for side effects from the study medicines.
Participants will visit the hospital for a check-up 14 days later.
The drug being tested in this study is called TAK-951. TAK-951 is being tested for prophylaxis for postoperative nausea and vomiting in high-risk participants.
The study will enroll a maximum of 160 patients, to allow a sample size of up to approximately 100 participants who have received both doses of Double-blind study drug/matching placebo. Participants will be randomly assigned in a 1:1 ratio to either Treatment Group A or Treatment Group B which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
This trial will be conducted in the United States. The overall time to participate in the study from the time of surgery to completion is approximately 14 days. Participants will make multiple visits to the clinic and will be contacted by telephone after receiving their last dose of the drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with 3 or more Apfel risk factors defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received prophylaxis with ondansetron 4 mg, intravenously (IV) immediately before induction and TAK-951 placebo subcutaneously (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).
Drug: Ondansetron · Drug: TAK-951 Placebo
Participants received prophylaxis with ondansetron placebo IV immediately before induction and TAK 951 4 mg, SC, approximately 30 to 45 minutes before the end of surgery (wound closure).
Drug: TAK-951 · Drug: Ondansetron Placebo
TAK-951 SC injection
Ondansetron IV injection
Ondansetron placebo-matching IV injection
TAK-951 placebo-matching SC injection
Percentage of Participants With Complete Response in the Immediate Postoperative Period
Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: 6 hours post-surgery (Day 1)
Percentage of Participants With Complete Response Within 24 Hours Post-Surgery
Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 24 hours post-surgery (up to Day 2)
Percentage of Participants With Emesis in the First 6 Hours Post-Surgery
Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 6 hours post-surgery (Day 1)
Percentage of Participants With Emesis Within 24 Hours Post-Surgery
Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 24 hours post-surgery (up to Day 2)
Percentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery
Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 6 hours post-surgery (Day 1)
Percentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery
Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. CMH method was used for analysis. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 24 hours post-surgery (up to Day 2)
Percentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery
Percentage of participants to whom rescue therapy was given as per local standard of care guidelines were reported. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 24 hours post-surgery (up to Day 2)
Time From End of Surgery to First Emetic Event
Duration between end of wound closure to first emetic event i.e., vomiting or retching was reported. If a participant did not have an emetic event within 24 hours post-surgery, they were censored at 24 hours post-surgery. Cox proportional hazard model was used for analysis.
Time frame: Within 24 hours post-surgery (up to Day 2)
Peak Nausea Verbal Rating Scale (VRS) Score
VRS was used to score postoperative nausea on 11-point numerical scale. The score ranges from 0-10, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Higher score represents worsening of disease. Mixed-effects model for repeated measures (MMRM) was used for analysis. Least square mean (LSM) estimates extracted from MMRM are presented in the data table for each time point.
Time frame: 30 minutes; 1, 2, 6, and 24 hours post-surgery (up to Day 2)
Percentage of Participants With Total Response
Percentage of participants with total response, defined as no emesis, no nausea (VRS score \<1), and no need for rescue therapy were reported. VRS was used to score postoperative nausea on 11-point numerical scale, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: Within 24 hours post-surgery (up to Day 2)
TAK-951 Plasma Concentrations
Time frame: 1-3, 4-6, 7-9, 10-18, and 22-26 hours post-dose (up to Day 2)
Percentage of Participants With Any Treatment Emergent Adverse Event (TEAE)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest single decimal.
Time frame: From first administration of study drug up to Day 14
Percentage of Participants With Markedly Abnormal Vital Signs
Vital signs included heart rate, respiratory rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), body temperature and BMI. Percentage of participants with markedly abnormal vital sign values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.
Time frame: From first administration of study drug up to Day 14
Percentage of Participants With Clinically Significant Electrocardiogram (ECG)
Percentage of participants with clinically significant ECG interpretation were reported. Percentages are rounded off to whole number at the nearest single decimal. A combined ECG interpretation was derived using ECG heart rate, PR interval, RR interval, QRS duration, QT interval, and QT interval with Fridericia correction method (QTcF).
Time frame: From first administration of study drug up to Day 14
Percentage of Participants With Markedly Abnormal Clinical Laboratory Values
Laboratory parameters included hematology and serum chemistry. Percentage of participants with markedly abnormal clinical laboratory values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.
Time frame: From first administration of study drug up to Day 14
Percentage of Participants With TAK-951 Antidrug Antibodies (ADA)
Percentage of participants with ADA results as: ADA negative, ADA positive were reported. Participants with ADA positive status are defined as those who had confirmed positive ADA status in baseline or at least 1 postbaseline assessments. Participants with ADA negative status are defined as those who did not have positive ADA response at baseline and in all postbaseline assessments.
Time frame: Within 6 hours post-surgery (Day 1)
Participants took part in the study at 7 sites in the United States from 20 October 2020 to 21 March 2022. Participants with a diagnosis of postoperative nausea and vomiting (PONV) were enrolled in 1:1 ratio.
| Milestone | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Started | 44 | 45 |
| Full analysis set (fas) | 41 | 39 |
| Pharmacokinetic (pk) set | 0 | 21 |
| Immunogenicity set | 0 | 21 |
| Unintended mis-dose due to dosing error | 0 | 18 |
| Completed | 38 | 36 |
| Not completed | 6 | 9 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Reason not specified | 3 | 6 |
Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Complete Response in the Immediate Postoperative Period | 48.8 (0.335 to 0.641) | 71.8 (0.577 to 0.859) |
Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Complete Response Within 24 Hours Post-Surgery | 41.5 (0.264 to 0.565) | 59.0 (0.435 to 0.744) |
Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Emesis in the First 6 Hours Post-Surgery | 17.1 (0.056 to 0.286) | 7.7 (0.016 to 0.209) |
Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Emesis Within 24 Hours Post-Surgery | 24.4 (0.112 to 0.375) | 10.3 (0.029 to 0.242) |
Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery | 41.5 (0.264 to 0.565) | 59.0 (0.435 to 0.744) |
Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. CMH method was used for analysis. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery | 34.1 (0.196 to 0.487) | 48.7 (0.330 to 0.644) |
Percentage of participants to whom rescue therapy was given as per local standard of care guidelines were reported. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery | 56.1 (0.409 to 0.713) | 33.3 (0.185 to 0.481) |
Duration between end of wound closure to first emetic event i.e., vomiting or retching was reported. If a participant did not have an emetic event within 24 hours post-surgery, they were censored at 24 hours post-surgery. Cox proportional hazard model was used for analysis.
| hours | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Time From End of Surgery to First Emetic Event | NA (NA to NA) | NA (NA to NA) |
VRS was used to score postoperative nausea on 11-point numerical scale. The score ranges from 0-10, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Higher score represents worsening of disease. Mixed-effects model for repeated measures (MMRM) was used for analysis. Least square mean (LSM) estimates extracted from MMRM are presented in the data table for each time point.
| score on a scale | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| 30 Minutes Post Surgery | 0.159 ± 0.227 | 0.347 ± 0.184 |
| 1 Hour Post Surgery | 0.099 ± 0.254 | 0.500 ± 0.204 |
| 2 Hours Post Surgery | 0.043 ± 0.201 | 0.308 ± 0.162 |
| 6 Hours Post Surgery | -0.020 ± 0.073 | 0.077 ± 0.059 |
| 24 Hours Post Surgery | 0.203 ± 0.142 | 0.000 ± 0.117 |
Percentage of participants with total response, defined as no emesis, no nausea (VRS score \<1), and no need for rescue therapy were reported. VRS was used to score postoperative nausea on 11-point numerical scale, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC |
|---|---|---|
| Percentage of Participants With Total Response | 34.1 (0.196 to 0.487) | 48.7 (0.330 to 0.644) |
| picograms per milliliter(pg/mL) | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|
| 1-3 Hours Post Dose | 24734.50 ± 14782.359 | 58229.41 ± 42971.281 |
| 4-6 Hours Post Dose | 18456.11 ± 13906.450 | 36950.00 ± 26649.650 |
| 7-9 Hours Post Dose | 10568.31 ± 8140.684 | 17741.76 ± 9705.848 |
| 10-18 Hours Post Dose | 4478.22 ± 2433.185 | — |
| 22-26 Hours Post Dose | 672.63 ± 699.161 | — |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest single decimal.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|---|
| Percentage of Participants With Any Treatment Emergent Adverse Event (TEAE) | 87.8 | 71.4 | 88.9 |
Vital signs included heart rate, respiratory rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), body temperature and BMI. Percentage of participants with markedly abnormal vital sign values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|---|
| Heart Rate (beats per minute [beats/min]): Low: <60 | 36.6 | 19.0 | 22.2 |
| Heart Rate (beats/min): High: >100 | 14.6 | 66.7 | 72.2 |
| Respiratory Rate (breaths per minute [breaths/min]): Low: <12 | 46.3 | 19.0 | 55.6 |
| Respiratory Rate (breaths/min): High: >16 | 100.0 | 100.0 | 100.0 |
| SBP (millimeters of mercury [mmHg]): Low: <85 | 7.3 | 9.5 | 16.7 |
| SBP (mmHg): High: >140 | 70.7 | 42.9 | 77.8 |
| DBP (mmHg): Low: <50 | 22.0 | 33.3 | 55.6 |
| DBP (mmHg): High: >90 | 43.9 | 14.3 | 38.9 |
| BMI (kg/m^2): High: >25.0 | 90.2 | 85.7 | 88.9 |
Percentage of participants with clinically significant ECG interpretation were reported. Percentages are rounded off to whole number at the nearest single decimal. A combined ECG interpretation was derived using ECG heart rate, PR interval, RR interval, QRS duration, QT interval, and QT interval with Fridericia correction method (QTcF).
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|---|
| Percentage of Participants With Clinically Significant Electrocardiogram (ECG) | 2.4 | 0.0 | 0.0 |
Laboratory parameters included hematology and serum chemistry. Percentage of participants with markedly abnormal clinical laboratory values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.
| percentage of participants | Ondansetron 4 mg IV | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|---|
| Erythrocytes (10^12 per liter [10^12/L]): Low: <0.8*Lower Limit of Normal (LLN) | 14.6 | 14.3 | 27.8 |
| Hemoglobin (grams per liter [g/L]): Low: <0.8*LLN | 14.6 | 23.8 | 11.1 |
| Hematocrit (percent [%]): Low: <0.8*LLN | 12.2 | 23.8 | 11.1 |
| Aspartate Aminotransferase (units per liter[U/L]): High: >3*Upper Limit of Normal (ULN) | 0.0 | 4.8 | 0.0 |
| Alanine Aminotransferase (U/L): High: >3*ULN | 0.0 | 4.8 | 0.0 |
| Albumin (g/L): Low: <25 | 0.0 | 4.8 | 0.0 |
| Protein (g/L): Low: <0.8*LLN | 2.4 | 4.8 | 16.7 |
| Gamma Glutamyl Transferase (U/L): High: >3*ULN | 0.0 | 5.0 | 0.0 |
| Glucose (millimoles per liter [mmol/L]): Low: <3 | 0.0 | 4.8 | 0.0 |
| Glucose (millimoles per liter [mmol/L]): High: >10 | 4.9 | 0.0 | 0.0 |
| Potassium (mmol/L): High: >5.5 | 2.4 | 0.0 | 0.0 |
Percentage of participants with ADA results as: ADA negative, ADA positive were reported. Participants with ADA positive status are defined as those who had confirmed positive ADA status in baseline or at least 1 postbaseline assessments. Participants with ADA negative status are defined as those who did not have positive ADA response at baseline and in all postbaseline assessments.
| percentage of participants | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|
| Any Antidrug Antibody Positive | 0.0 | 0.0 |
| Any Antidrug Antibody Negative | 100.0 | 100.0 |
Collected over From first administration of study drug up to Day 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ondansetron 4 mg IV | 0/41 (0%) | 0/41 (0%) | 36/41 (87.8%) |
| TAK-951 4 mg SC | 0/21 (0%) | 0/21 (0%) | 15/21 (71.4%) |
| TAK-951 Redacted mg SC | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Event | Ondansetron 4 mg IV | TAK-951 4 mg SC | TAK-951 Redacted mg SC |
|---|---|---|---|
| Sinus tachycardiaCardiac disorders | 4/41 | 6/21 | 10/18 |
| Procedural hypotensionInjury, poisoning and procedural complications | 16/41 | 8/21 | 6/18 |
| HypotensionVascular disorders | 3/41 | 1/21 | 7/18 |
| FlatulenceGastrointestinal disorders | 6/41 | 6/21 | 1/18 |
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 6/41 | 0/21 | 4/18 |
| TachycardiaCardiac disorders | 0/41 | 0/21 | 3/18 |
| HypertensionVascular disorders | 1/41 | 0/21 | 2/18 |
| BradycardiaCardiac disorders | 4/41 | 0/21 | 0/18 |
| ChillsGeneral disorders | 1/41 | 2/21 | 0/18 |
| PruritusSkin and subcutaneous tissue disorders | 1/41 | 1/21 | 1/18 |
FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.
| Age, Continuous(years) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Mean | 46.0 ± 10.32 | 45.1 ± 10.57 | 45.6 ± 10.39 |
| Sex: Female, Male(Participants) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Female | 38 | 38 | 76 |
| Male | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 17 |
| Not Hispanic or Latino | 33 | 29 | 62 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 10 | 18 |
| White | 31 | 27 | 58 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(Participants) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| United States | 41 | 39 | 80 |
| Weight(kg) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Mean | 93.85 ± 27.439 | 87.61 ± 22.258 | 90.81 ± 25.087 |
| Height(cm) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Mean | 164.57 ± 8.448 | 164.32 ± 9.499 | 164.44 ± 8.919 |
| Body Mass Index (BMI)(kg/m^2) | Ondansetron 4 mg IV | TAK-951 4 mg SC | Total |
|---|---|---|---|
| Mean | 34.41 ± 8.909 | 32.47 ± 7.574 | 33.47 ± 8.290 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2020 to primary completion in Mar 2022, 16 months.
Results were first posted in Apr 2023, 1 year 1 month after primary completion.
Of 17 phase 2 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 29. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: TAK-951 · Ondansetron
Postoperative Nausea and Vomiting →